Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer

Completed · Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Celecoxib may be effective in preventing the further development of cancer. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining trastuzumab with celecoxib may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining celecoxib and trastuzumab in treating women who have metastatic breast cancer that has not responded to previous trastuzumab.

Key facts

Study ID

NCT00006381

Run by

Memorial Sloan Kettering Cancer Center

Starts

2000-06-01

Expected to finish

2004-02-01

Last updated by the study team

2013-12-19

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.